suvorexant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
orexin receptor antagonists	4881	1030377-33-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: MK 4305 suvorexant belsomra MK-4305	a highly selective antagonist for orexin receptors OX1R and OX2R, the orexin neuropeptide signaling system is a central promoter of wakefulness, blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive Molecular weight: 450.93 Formula: C23H23ClN6O2 CLOGP: 5.10 LIPINSKI: 0 HAC: 8 HDO: 0 TPSA: 80.29 ALOGS: -3.58 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

MK 4305
suvorexant
belsomra
MK-4305

a highly selective antagonist for orexin receptors OX1R and OX2R, the orexin neuropeptide signaling system is a central promoter of wakefulness, blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive

Molecular weight: 450.93
Formula: C23H23ClN6O2
CLOGP: 5.10
LIPINSKI: 0
HAC: 8
HDO: 0
TPSA: 80.29
ALOGS: -3.58
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
t_half (Half-life)	10.37 hours	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.84 mL/min/kg	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.69 L/kg	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	0.62 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 5 of 5 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Aug. 13, 2014	FDA	MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	503.28	20.54	536	5246	1044229	62439011
Nightmare	172.13	20.54	65	5717	19129	63464111
Abnormal dreams	156.90	20.54	52	5730	10464	63472776
Sleep paralysis	138.03	20.54	27	5755	633	63482607
Somnolence	128.97	20.54	116	5666	178569	63304671
Poor quality sleep	95.05	20.54	43	5739	19892	63463348
Wrong technique in product usage process	92.17	20.54	62	5720	62278	63420962
No adverse event	91.06	20.54	53	5729	41352	63441888
Feeling abnormal	72.61	20.54	78	5704	148314	63334926
Product dose omission issue	71.71	20.54	97	5685	234216	63249024

Showing 1 to 10 of 32 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	363.77	21.37	328	3317	456423	34496863
Nightmare	148.60	21.37	56	3589	14335	34938951
Abnormal dreams	94.85	21.37	34	3611	7544	34945742
Somnolence	82.94	21.37	78	3567	111038	34842248
Poor quality sleep	77.51	21.37	30	3615	8226	34945060
Wrong technique in product usage process	63.40	21.37	42	3603	35944	34917342
Sleep paralysis	52.60	21.37	10	3635	174	34953112
Delirium	51.39	21.37	40	3605	43951	34909335
Hepatic function abnormal	51.09	21.37	40	3605	44323	34908963
No adverse event	48.39	21.37	30	3615	22897	34930389

Showing 1 to 10 of 21 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	621.53	18.42	649	7611	1080264	78655864
Nightmare	272.52	18.42	102	8158	25759	79710369
Abnormal dreams	188.89	18.42	63	8197	11349	79724779
Somnolence	168.24	18.42	162	8098	238819	79497309
Sleep paralysis	153.66	18.42	30	8230	608	79735520
Poor quality sleep	133.62	18.42	59	8201	22663	79713465
Wrong technique in product usage process	108.72	18.42	77	8183	73798	79662330
Feeling abnormal	76.16	18.42	88	8172	159111	79577017
Delirium	72.19	18.42	64	8196	84563	79651565
Hallucination	69.49	18.42	63	8197	85682	79650446

Showing 1 to 10 of 33 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N05CM19	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Other hypnotics and sedatives
CHEBI has role	CHEBI:35488	central nervous system depressants
CHEBI has role	CHEBI:83296	orexin receptor antagonists
FDA EPC	N0000191000	Orexin Receptor Antagonist
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000190114	Cytochrome P450 3A Inhibitors
FDA MoA	N0000190998	Orexin Receptor Antagonists
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D006993	Hypnotics and Sedatives

Showing 1 to 10 of 13 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Insomnia	indication	193462001
Narcolepsy	contraindication	60380001	DOID:8986

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.96	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG	BELSOMRA	MERCK SHARP DOHME	N204569	Aug. 13, 2014	RX	TABLET	ORAL	7951797	Nov. 20, 2029	TREATMENT OF INSOMNIA
15MG	BELSOMRA	MERCK SHARP DOHME	N204569	Aug. 13, 2014	RX	TABLET	ORAL	7951797	Nov. 20, 2029	TREATMENT OF INSOMNIA
20MG	BELSOMRA	MERCK SHARP DOHME	N204569	Aug. 13, 2014	RX	TABLET	ORAL	7951797	Nov. 20, 2029	TREATMENT OF INSOMNIA
5MG	BELSOMRA	MERCK SHARP DOHME	N204569	Aug. 13, 2014	RX	TABLET	ORAL	7951797	Nov. 20, 2029	TREATMENT OF INSOMNIA

Showing 1 to 4 of 4 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10MG	BELSOMRA	MERCK SHARP DOHME	N204569	Aug. 13, 2014	RX	TABLET	ORAL	Jan. 29, 2023	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE
15MG	BELSOMRA	MERCK SHARP DOHME	N204569	Aug. 13, 2014	RX	TABLET	ORAL	Jan. 29, 2023	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE
20MG	BELSOMRA	MERCK SHARP DOHME	N204569	Aug. 13, 2014	RX	TABLET	ORAL	Jan. 29, 2023	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE
5MG	BELSOMRA	MERCK SHARP DOHME	N204569	Aug. 13, 2014	RX	TABLET	ORAL	Jan. 29, 2023	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE

Showing 1 to 4 of 4 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Orexin receptor type 1	GPCR	O43613	OX1R_HUMAN	ANTAGONIST	Ki	9.26	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Orexin receptor type 2	GPCR	O43614	OX2R_HUMAN	ANTAGONIST	Ki	9.46	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Orexin receptor type 2	GPCR		OX2R_MOUSE		Ki	8.06	CHEMBL
Orexin receptor type 1	GPCR		OX1R_MOUSE		Ki	8.77	CHEMBL

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
SUV	PDB_CHEM_ID
015650	NDDF
081L192FO9	UNII
1547099	RXNORM
227824	MMSL
24965990	PUBCHEM_CID
2890	IUPHAR_LIGAND_ID
30487	MMSL
4033910	VUID
4033910	VANDF

Showing 1 to 10 of 21 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BELSOMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0005	TABLET, FILM COATED	5 mg	ORAL	NDA	36 sections
BELSOMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0005	TABLET, FILM COATED	5 mg	ORAL	NDA	36 sections
BELSOMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0005	TABLET, FILM COATED	5 mg	ORAL	NDA	36 sections
BELSOMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0033	TABLET, FILM COATED	10 mg	ORAL	NDA	36 sections
BELSOMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0033	TABLET, FILM COATED	10 mg	ORAL	NDA	36 sections
BELSOMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0033	TABLET, FILM COATED	10 mg	ORAL	NDA	36 sections
BELSOMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0325	TABLET, FILM COATED	15 mg	ORAL	NDA	36 sections
BELSOMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0325	TABLET, FILM COATED	15 mg	ORAL	NDA	36 sections
BELSOMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0325	TABLET, FILM COATED	15 mg	ORAL	NDA	36 sections
BELSOMRA	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0335	TABLET, FILM COATED	20 mg	ORAL	NDA	36 sections

Showing 1 to 10 of 12 entries

Previous1 2Next